Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sequential Neoadjuvant Ifosfamide and Doxorubicin in Localized High-grade Soft Tissue Sarcoma
NCT04776525Phase 2Recruiting
- Sponsor
- Oslo University Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2027
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
A Phase 2 trial of ifosfamide, pegylated liposomal doxorubicin in soft tissue sarcoma (STS), sponsored by Oslo University Hospital. Started Apr 2021; status: recruiting.
02
Drugs
ifosfamidepegylated liposomal doxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT04776525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04776525.